Bristol-Myers Squibb announces plans for third quarter submission of a biologics license application for opdivo® (nivolumab)
11 July 2014 | By Bristol-Myers Squibb
...an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma...